Seegene Completes $16.6M IPO on Korea's KOSDAQ | GenomeWeb

This article was originally posted on Sept. 13.

Molecular diagnostics firm Seegene this week announced the completion of a $16.6 million initial public offering on the Korea Securities Dealers Automated Quotations.

The company, which was founded in Seoul, Korea, in 2000 and has a subsidiary in Rockville, Md., said it will use the cash infusion to expand its international market presence, with an emphasis on the US and Japan, where it is seeking regulatory approval for a number of multiplex PCR-based diagnostic tests.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.